TW200306177A - Method of treating tinnitus - Google Patents

Method of treating tinnitus Download PDF

Info

Publication number
TW200306177A
TW200306177A TW092102235A TW92102235A TW200306177A TW 200306177 A TW200306177 A TW 200306177A TW 092102235 A TW092102235 A TW 092102235A TW 92102235 A TW92102235 A TW 92102235A TW 200306177 A TW200306177 A TW 200306177A
Authority
TW
Taiwan
Prior art keywords
acid
methyl
aminomethyl
aminemethyl
acetic acid
Prior art date
Application number
TW092102235A
Other languages
English (en)
Chinese (zh)
Inventor
David James Dooley
David Juergen Wustrow
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27663234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200306177(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of TW200306177A publication Critical patent/TW200306177A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW092102235A 2002-01-31 2003-01-30 Method of treating tinnitus TW200306177A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35363202P 2002-01-31 2002-01-31

Publications (1)

Publication Number Publication Date
TW200306177A true TW200306177A (en) 2003-11-16

Family

ID=27663234

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092102235A TW200306177A (en) 2002-01-31 2003-01-30 Method of treating tinnitus

Country Status (16)

Country Link
US (2) US7026505B2 (enExample)
EP (1) EP1469841A1 (enExample)
JP (1) JP2005521664A (enExample)
KR (1) KR20040081478A (enExample)
CN (1) CN1625393A (enExample)
AU (1) AU2003201716B2 (enExample)
BR (1) BR0307411A (enExample)
CA (1) CA2474000A1 (enExample)
CL (1) CL2008000613A1 (enExample)
IL (1) IL162028A0 (enExample)
MX (1) MXPA04004105A (enExample)
NZ (1) NZ532624A (enExample)
PL (1) PL371944A1 (enExample)
TW (1) TW200306177A (enExample)
WO (1) WO2003063845A1 (enExample)
ZA (1) ZA200403069B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (en) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba and its derivatives for the treatment of pain
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2004078734A1 (en) 2003-03-07 2004-09-16 Warner-Lambert Company Llc TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES
EP1622569B1 (en) 2003-04-24 2015-12-02 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metallproteases
WO2005013888A2 (en) * 2003-05-14 2005-02-17 Cytokinetics, Inc. Compounds, compositions and methods
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
CN101506140B (zh) * 2006-08-24 2014-06-18 百时美施贵宝公司 环状11β-羟类固醇脱氢酶Ⅰ型抑制剂
WO2008060572A1 (en) * 2006-11-14 2008-05-22 Xenoport, Inc. Use of gabapentin and pregabalin prodrugs for treating tinnitus
CA2672044A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
ITMI20071492A1 (it) 2007-07-24 2009-01-25 S I I T Srl Servizio Internazi "composizioni per il trattamento e la prevenzione di condizioni di vertigine e acufeni comprendenti citicolina, estratto di ginkgo biloba e flavoni dimerici di ginkgo biloba"
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
CN101260063B (zh) * 2008-03-21 2013-06-19 北京润德康医药技术有限公司 γ-氨基丁酸衍生物及其制备方法
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
CN111718379A (zh) * 2019-03-19 2020-09-29 海南长安国际制药有限公司 具有l1和l2结构的铂类物质及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
NZ334898A (en) * 1996-10-23 2000-09-29 Warner Lambert Co Substituted gamma aminobutyric acids as pharamceutical agents
NZ503963A (en) * 1997-12-16 2002-09-27 Warner Lambert Co 1-substituted-1-aminomethyl-cycloalkane derivatives, or gabapentin analogues, preparation and use in the treatment of neurological disorders
CN1279667A (zh) * 1997-12-16 2001-01-10 沃尼尔·朗伯公司 4(3)取代-4(3)-氨基甲基-(硫代)吡喃(噻喃)或-哌啶衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途
WO1999031074A2 (en) * 1997-12-16 1999-06-24 Warner-Lambert Company ((cyclo)alkyl substituted)-.gamma.-aminobutyric acid derivatives (=gaba analogues), their preparation and their use in the treatment of neurological disorders
JP2002516312A (ja) 1998-05-26 2002-06-04 ワーナー−ランバート・カンパニー カルシウムチャンネルのα2δサブユニットに対する親和性を有する立体配座的に制約されたアミノ酸化合物
GB9821179D0 (en) * 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
CZ300834B6 (cs) * 1999-06-10 2009-08-19 Warner-Lambert Company Llc Mono- a disubstituované kyseliny 3-propyl-gamma-aminomáselné
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
US6620829B2 (en) * 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage

Also Published As

Publication number Publication date
NZ532624A (en) 2007-05-31
ZA200403069B (en) 2005-04-22
CL2008000613A1 (es) 2008-11-07
US7026505B2 (en) 2006-04-11
US7138542B2 (en) 2006-11-21
JP2005521664A (ja) 2005-07-21
BR0307411A (pt) 2004-12-07
US20030176504A1 (en) 2003-09-18
PL371944A1 (en) 2005-07-11
IL162028A0 (en) 2005-11-20
AU2003201716B2 (en) 2008-04-17
CA2474000A1 (en) 2003-08-07
EP1469841A1 (en) 2004-10-27
US20060100281A1 (en) 2006-05-11
MXPA04004105A (es) 2004-11-29
CN1625393A (zh) 2005-06-08
WO2003063845A1 (en) 2003-08-07
KR20040081478A (ko) 2004-09-21

Similar Documents

Publication Publication Date Title
ES3040534T3 (en) Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
US8927553B2 (en) Deuterium-enriched alkyl sulfonamides and uses thereof
CN105899498B (zh) 用于合成吲哚胺2,3-双加氧酶抑制剂的方法
ES2972533T3 (es) Moduladores del receptor de NMDA a base de espirolactama, y sus usos
CA3001703C (en) Modulators of sestrin-gator2 interaction and uses thereof
CN109069508A (zh) Ezh2抑制剂及其用途
US9763912B2 (en) Compositions, methods of use, and methods of treatment
HUE025013T2 (hu) Szulfonamid-származékok
UA119247C2 (uk) Спіроциклічні сполуки як інгібітори триптофангідроксилази
ES2925550T3 (es) Trastornos neurodegenerativos
JP6517833B2 (ja) 神経変性疾患の処置に有用なウィザノライド
US20250325469A1 (en) Inhibitors of atp synthase - cosmetic and therapeutic uses
JP6692751B2 (ja) 新規カベオリンモジュレーターを使用する自己免疫および/または炎症疾患の治療
TWI345465B (en) Proteasome inhibitors and methods of using the same
US10961231B2 (en) NTCP inhibitors
CN109415356A (zh) 4-(5-(4,7-二甲基苯并呋喃-2-基)-1,2,4-噁二唑-3-基)苯甲酸的结晶形式及其制备方法
JP7630540B2 (ja) 神経保護ペプチド
ES2402112T3 (es) Cocristales de tramadol y coxibs
e Silva et al. Trans-scleral delivery of polyamine analogs for ocular neovascularization
TWI803858B (zh) 化合物及其醫藥用途
US20240374617A1 (en) Methods of activating microglial cells
US11180499B2 (en) Phosphodiesterase inhibitors
ES2909707T3 (es) Mofezolaco y dos derivados para su uso en el tratamiento de la neuroinflamación
CA3215697A1 (en) Soluble adenylyl cyclase (sac) inhibitors and uses thereof
JP2024531809A (ja) 運動ニューロン変性の処置又は神経保護において使用するためのオキサジアザスピロ化合物